《臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件》由會(huì)員分享，可在線閱讀，更多相關(guān)《臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件（43頁珍藏版）》請(qǐng)?jiān)谘b配圖網(wǎng)上搜索。

1、,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,

2、,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,,,,單擊此處編輯母版標(biāo)題樣式,單擊此處編輯母版文本樣式,第二級(jí),第三級(jí),第四級(jí),第五級(jí),*,,*,臨床醫(yī)學(xué)文獻(xiàn)檢索、閱讀、評(píng)價(jià)與應(yīng)用,,臨床醫(yī)學(xué)文獻(xiàn)檢索、閱讀、評(píng)價(jià)與應(yīng)用,1,檢索途徑,題錄型數(shù)據(jù)庫,中國(guó)

3、生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）,Medline,全文型數(shù)據(jù)庫,中文科技期刊數(shù)據(jù)庫（VIP）,萬方數(shù)據(jù)知識(shí)平臺(tái),中國(guó)知網(wǎng)（CNKI）,,檢索途徑題錄型數(shù)據(jù)庫,2,Medline,檢索,,Medline檢索,3,,,,,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,4,,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,5,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,6,,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,7,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,8,,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,9,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,10,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件

4、,11,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,12,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,13,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,14,保存和跟蹤檢索結(jié)果,,保存和跟蹤檢索結(jié)果,15,,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,16,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,17,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,18,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,19,獲取全文的途徑,,獲取全文的途徑,20,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,21,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,22,,臨床醫(yī)學(xué)文獻(xiàn)檢索閱讀評(píng)價(jià)和應(yīng)用ppt課件,23,其

5、他途徑,中國(guó)科學(xué)院上海生命科學(xué)研究院,復(fù)旦大學(xué)上海醫(yī)學(xué)院,上海圖書館,交通大學(xué),其他途徑中國(guó)科學(xué)院上海生命科學(xué)研究院,24,,Google,題目,英文關(guān)鍵詞,filetype:PDF,聯(lián)系作者,論壇,代理,,Google,25,重要工具,《華東地區(qū)西文生物醫(yī)學(xué)期刊館藏聯(lián)合目錄》,各家圖書館訂閱的外文期刊紙質(zhì)版,復(fù)旦大學(xué)醫(yī)科圖書館有電子檢索,,重要工具《華東地區(qū)西文生物醫(yī)學(xué)期刊館藏聯(lián)合目錄》,26,閱讀的目的,了解臨床證據(jù)---Cochrane Library，Clinical Evidence，高IF SCI論文,最新進(jìn)展—Pubmed-Abstract,研究方法—Methods,講演、興趣—

6、-精讀,了解背景---Introduction,相互比較---Discussion,評(píng)價(jià)質(zhì)量---Methods,閱讀的目的了解臨床證據(jù)---Cochrane Library,27,文章的結(jié)構(gòu),Title and running title,Authors and addresses,Abstract,Keywords and abbreviations,Introduction,Materials and methods,Results,Discussion,Acknowledgments,References,Tables and figures,文章的結(jié)構(gòu)Title and runnin

7、g title,28,,,,Title,,Abstract,,Figures,,Tables,,Results and discussion,,Rest of the paper,(J.K. Ladha),Title(J.K. Ladha),29,影響因子（,Impact Factor,）,發(fā)表文章篇數(shù)：,2009=597，2019=577；合計(jì)=1174,2019年引用次數(shù)：,2009=4341，2019=4122；合計(jì)=8463,,IF=8463/1174=7.209,,2019年6月中下旬公布,影響因子（Impact Factor）發(fā)表文章篇數(shù)：,30,文章質(zhì)量評(píng)價(jià),Jadad評(píng)分,Co

8、chrane Handbook,Cochrane Back Review Group,CONSORT聲明,文章質(zhì)量評(píng)價(jià)Jadad評(píng)分,31,Jadad,評(píng)分,隨機(jī)分組序列的產(chǎn)生方法,2分：計(jì)算機(jī)或隨機(jī)數(shù)字表,1分：提到隨機(jī)，但未詳細(xì)說明,0分：半隨機(jī)或未隨機(jī),雙盲,2分：描述了實(shí)施雙盲的具體方法并且被認(rèn)為是恰當(dāng)?shù)模绮捎猛耆恢碌陌参縿┑?1分：試驗(yàn)僅提及采用雙盲法,0,分：試驗(yàn)提及采用雙盲，但方法不恰當(dāng)，如比較片劑與注射劑而未提及使用雙偽法,退出與失訪,1分：詳細(xì)說明了退出與失訪的理由,0分：沒有提及,Jadad 評(píng)分隨機(jī)分組序列的產(chǎn)生方法,32,Cochrane Back,,Review

9、Group,Furlan AD, Pennick V, Bombardier C, van Tulder M, the Editorial Board of the Cochrane Back Review Group. 2009 Updated method guidelines for systematic reviews in the Cochrane Back Review Group.,Spine 2009;34(18):1929–41.,Cochrane Back Review GroupFurl,33,CONSORT,清單詳細(xì)內(nèi)容,CONSORT清單詳細(xì)內(nèi)容,34,引言,Broa

10、d information on topic,Previous research,Narrower background information,Need for study,Focus of paper,Hypothesis,and Purpose,,引言Broad information on topic,35,,Surgery is the treatment of choice for patients with disease stage I and II non-small cell lung cancer (NSCLC) … An NSCLC meta-analysis comb

11、ined the results from eight randomised trials of surgery versus surgery plus adjuvant cisplatin-based chemotherapy and showed a small, but not significant (p=0.08), absolute survival benefit of around 5% at 5 years (from 50% to 55%). At the time the current trial was designed (mid-1990s), adjuvant c

12、hemotherapy had not become standard clinical practice … The clinical rationale for neo-adjuvant chemotherapy is three-fold: regression of the primary cancer could be achieved thereby facilitating and simplifying or reducing subsequent surgery; undetected micro-metastases could be dealt with at the s

13、tart of treatment; and there might be inhibition of the putative stimulus to residual cancer by growth factors released by surgery and by subsequent wound healing …,The current trial was therefore set up to compare, in patients with resectable NSCLC, surgery alone versus three cycles of platinum-bas

14、ed chemotherapy followed by surgery in terms of overall survival, quality of life, pathological staging, resectability rates, extent of surgery, and time to and site of relapse.,Surgery is the treatment of ch,36,CONSORT,清單詳細(xì)內(nèi)容,CONSORT清單詳細(xì)內(nèi)容,37,CONSORT,清單詳細(xì)內(nèi)容（續(xù)一）,CONSORT清單詳細(xì)內(nèi)容（續(xù)一）,38,CONSORT,清單詳細(xì)內(nèi)容（續(xù)

15、二）,CONSORT清單詳細(xì)內(nèi)容（續(xù)二）,39,CONSORT,清單詳細(xì)內(nèi)容（,End,）,CONSORT Group. CONSORT 2019 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med. 2019;152.,David Moher, et al. CONSORT 2019 Explanation and Elaboration: updated guidelines for reporting parallel group randomised t

16、rials. BMJ 2019;340:c869,CONSORT清單詳細(xì)內(nèi)容（End）CONSORT Grou,40,評(píng)價(jià)對(duì)象例數(shù),n,=,排除例數(shù),n,=,例，,不符合 例，拒絕參與 例，其它原因 例。,隨機(jī)分組例數(shù),n,=,分配至實(shí)驗(yàn)組例數(shù),n,=,接受分配 例,,,不接受分配 例,…,分配至對(duì)照組例數(shù),n,=,接受分配 例,,,不接受分配 例,…,失訪例數(shù),n,=,未依從計(jì)劃 例,失訪例數(shù),n,=,未依從計(jì)劃 例,納入分析例數(shù),n,=,排除分析例數(shù),n,=,納入分析例數(shù),n,=,排除

17、分析例數(shù),n,=,CONSORT,流程圖,評(píng)價(jià)對(duì)象例數(shù)n=排除例數(shù)n= 例，隨機(jī)分組例數(shù)n=分配,41,好文章的要求（,4C,）,,Clear：思路清晰、邏輯性強(qiáng)、概念清楚、層次,清楚、表達(dá)清楚、語句通順,Complete：內(nèi)容完整、結(jié)構(gòu)完整，忌虎頭蛇尾,Correct：內(nèi)容正確，數(shù)據(jù)數(shù)據(jù)正確、可信，,文法正確,Concise：論述深刻、充分揭示其文章內(nèi)涵,好文章的要求（4C）,42,文章實(shí)例,Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan Yinqiaosan in the Treatment of H1N1 Influenza,Ann Intern Med,IF：16.729,文章實(shí)例Oseltamivir Compared With,43,